Form 4: AVITA Medical Director Suzanne Crowe Reports Acquisition of Equity Awards Following Stockholder Approval

AVITA Medical, Inc. Director Suzanne Crowe has reported the acquisition of 10,022 restricted stock units and 4,295 stock options, aligning her interests with the company's performance.

Summary

• Suzanne Crowe, a Director at AVITA Medical, Inc. (RCEL), reported the acquisition of 10,022 shares of Common Stock in the form of Restricted Stock Units (RSUs) on January 21, 2025.
• These RSUs represent a contingent right to be issued one share of Common Stock per RSU and are subject to time-based vesting criteria, vesting 12 months after the grant date of January 21, 2025.
• The grant of these RSUs was contingent on the approval of the Company's stockholders, which was obtained on June 4, 2025.
• Following this transaction, Suzanne Crowe beneficially owns 46,934 shares of Common Stock, which includes unvested RSUs and 22,990 of the Issuer's CDIs (translating to 4,598 Common Stock shares).
• Additionally, Ms. Crowe acquired 4,295 stock options on January 21, 2025, with an exercise price of $8.73 per share.
• These stock options become exercisable on January 21, 2026, and have an expiration date of January 21, 2035.
• The option grant was approved by the Board of Directors on January 6, 2025, with the exercise price set at the closing price of a Common Stock share on Nasdaq on the grant date ($8.73).
• Similar to the RSUs, this option grant was also subject to stockholder approval, which was secured on June 4, 2025.

Sentiment

Score: 5

Explanation: The document is a standard Form 4 filing detailing director compensation. It is neutral in sentiment as it reports a routine transaction and does not contain information that would typically be interpreted as positive or negative for the company's operational or financial performance.

Positives

• The grant of restricted stock units and stock options to a director aligns management and board interests with those of shareholders, incentivizing long-term performance.
• The compensation structure, including time-based vesting for RSUs and a 10-year expiration for options, encourages sustained commitment and value creation.

Future Outlook

This filing primarily details past compensation grants and does not provide forward-looking statements regarding company performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of director compensation in the form of equity awards, a common practice across publicly traded companies to incentivize leadership. It does not provide specific insights into broader industry trends or competitive positioning beyond the company's standard compensation practices.

Corporate Governance

Related Party Transactions

• The acquisition of Restricted Stock Units and stock options by Suzanne Crowe, a Director, represents a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with shareholder value creation, as the value of the awards is tied to the company's stock performance.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The granted Restricted Stock Units (RSUs) are expected to vest on January 21, 2026.
• The granted stock options will become exercisable on January 21, 2026, and will expire on January 21, 2035.

Key Dates

Keywords

AVITA Medical, RCEL, Form 4, SEC filing, insider transaction, restricted stock units, stock options, director compensation, equity award, corporate governance